Hoppa till innehållet

BioInvent International AB: BioStock: BioInvent's CEO comments on the study success in China

BioInvent's partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent's lead drug candidate BI-1206 in combination with rituximab in cancer patients with non-Hodgkin's lymphoma. BioStock reached out to BioInvent's CEO Martin Welschof, who expects that 2024 will be a break-out year for the company, with multiple data readouts expected during the second half of the year.

Read the full interview with Martin Welschof at biostock.se:

https://www.biostock.se/en/2024/03/bioinvents-ceo-comments-on-the-study-success-in-china/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Source:Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera